title: Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study.
abstract: BACKGROUND
  Tuberculosis (TB) and TB-human immunodeficiency virus infection (HIV) coinfection is a major public health concern in resource-limited settings. Although TB treatment is challenging in HIV-infected patients because of treatment interactions, immunopathological reactions, and concurrent infections, few prospective studies have addressed this in sub-Saharan Africa. In this study we aimed to determine incidence, causes of, and risk factors for serious adverse events among patients on first-line antituberculous treatment, as well as its impact on antituberculous treatment outcome.
  
  
  RESULTS
  Prospective observational cohort study of adults treated for TB at the Internal Medicine department of the Kigali University Hospital from May 2008 through August 2009. Of 263 patients enrolled, 253 were retained for analysis: median age 35 (Interquartile range, IQR 28-40), 55% male, 66% HIV-positive with a median CD4 count 104 cells/mm(3) (IQR 44-248 cells/mm(3)). Forty percent had pulmonary TB, 43% extrapulmonary TB and 17% a mixed form. Sixty-four (26%) developed a serious adverse event; 58/167 (35%) HIV-infected vs. 6/86 (7%) HIV-uninfected individuals. Commonest events were concurrent infection (n = 32), drug-induced hepatitis (n = 24) and paradoxical reactions/TB-IRIS (n = 23). HIV-infection (adjusted Hazard Ratio, aHR 3.4, 95% Confidence Interval, CI 1.4-8.7) and extrapulmonary TB (aHR 2, 95%CI 1.1-3.7) were associated with an increased risk of serious adverse events. For TB/HIV co-infected patients, extrapulmonary TB (aHR 2.0, 95%CI 1.1-3.9) and CD4 count <100 cells/mm3 at TB diagnosis (aHR 1.7, 95%CI 1.0-2.9) were independent predictors. Adverse events were associated with an almost two-fold higher risk of unsuccessful treatment outcome at 6 months (HR 1.89, 95%CI 1.3-3.0).
  
  
  CONCLUSIONS
  Adverse events frequently complicate the course of antituberculous treatment and worsen treatment outcome, particularly in patients with extrapulmonary TB and advanced immunodeficiency. Concurrent infection accounts for most events. Our data suggest that deterioration in a patient already receiving antituberculous treatment should prompt an aggressive search for additional infections.
authors: Internal Medicine Department, Centre Hospitalier Universitaire de Kigali, Kigali, Rwanda. nlorent@itg.be
authors: Natalie
authors: N
authors: Lorent
authors: Osee
authors: O
authors: Sebatunzi
authors: Gloria
authors: G
authors: Mukeshimana
authors: Jef
authors: J
authors: Van den Ende
authors: Joannes
authors: J
authors: Clerinx
references: Int J Tuberc Lung Dis. 2007 Nov;11(11):1203-9
references: 17958982
references: Int J Tuberc Lung Dis. 2001 Nov;5(11):1000-5
references: 11716335
references: Lancet Infect Dis. 2009 Sep;9(9):577-82
references: 19695494
references: J Infect. 2006 Dec;53(6):357-63
references: 16487593
references: Int J Tuberc Lung Dis. 2009 Mar;13(3):360-6
references: 19275797
references: Trop Med Int Health. 2007 Jul;12(7):852-5
references: 17596252
references: BMC Infect Dis. 2010 Mar 30;10:83
references: 20353569
references: J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1574-6
references: 15577411
references: Am J Respir Crit Care Med. 2003 Jun 1;167(11):1472-7
references: 12569078
references: Int J Tuberc Lung Dis. 2006 Sep;10(9):946-53
references: 16964782
references: Curr Opin HIV AIDS. 2010 Jan;5(1):18-26
references: 20046144
references: HIV Med. 2000 Mar;1(2):107-15
references: 11737333
references: Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1871-6
references: 9620920
references: PLoS One. 2009;4(2):e4520
references: 19229341
references: Emerg Infect Dis. 2009 Feb;15(2):258-64
references: 19193270
references: Int J Tuberc Lung Dis. 2004 Dec;8(12):1499-505
references: 15636498
references: Int J Tuberc Lung Dis. 2008 Apr;12(4):392-6
references: 18371264
references: AIDS. 2005 Mar 4;19(4):399-406
references: 15750393
references: Lancet Infect Dis. 2010 Apr;10(4):251-61
references: 20334848
references: Am J Respir Crit Care Med. 2002 Oct 1;166(7):916-9
references: 12359646
references: AIDS. 2002 Jan 4;16(1):75-83
references: 11741165
references: Chest. 1992 Jun;101(6):1644-55
references: 1303622
references: AIDS. 2007 Nov 12;21(17):2362-3
references: 18090294
references: Lancet Infect Dis. 2010 Jun;10(6):417-32
references: 20510282
references: Lancet Infect Dis. 2008 Aug;8(8):516-23
references: 18652998
references: AIDS. 2007 Jan 30;21(3):335-41
references: 17255740
references: Am J Respir Crit Care Med. 1998 Jul;158(1):157-61
references: 9655723
references: Int J Tuberc Lung Dis. 2005 May;9(5):534-40
references: 15875925
references: Am J Respir Crit Care Med. 1999 Mar;159(3):733-40
references: 10051244
references: Thorax. 2006 Sep;61(9):791-4
references: 16844730
references: BMC Public Health. 2004 Dec 29;4:68
references: 15625004
references: Int J STD AIDS. 2009 May;20(5):339-45
references: 19386972
references: Int J Tuberc Lung Dis. 2007 Jan;11(1):78-84
references: 17217134
references: AIDS. 2004 Aug 20;18(12):1615-27
references: 15280772
references: Curr Opin HIV AIDS. 2007 Jul;2(4):339-45
references: 19372909